[{"orgOrder":0,"company":"TrialSpark","sponsor":"resTORbio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"resTORbio and TrialSpark Collaborate to Investigate RTB-101 for COVID-19 on the Project Covalence Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"TrialSpark","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TrialSpark Announces First Patient Dosed in Phase 2 Clinical Trial for ASN008-201 in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by TrialSpark
ASN008, a Phase 2-ready topical sodium channel blocker in development for atopic dermatitis. ASN008 has shown promising efficacy data in pruritus (itch) associated with atopic dermatitis.
TrialSpark's integrated tech platform and trial model will enable resTORbio to accelerate their clinical trials of RTB-101 for COVID-19 in community/outpatient settings.